Palvella Therapeutics, Inc. (PVLA) Current Ratio
- Current ratio · latest quarter: Value 21.18×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 21.18× | Current assets / current liabilities. $253.03M ÷ $11.95M ≈ 21.18× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 253.03M USD | Assets, Current |
| Current obligations | 11.95M USD | Liabilities, Current |
| Cash and equivalents | 187.80M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | 6.79M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $253.03M | $11.95M | $187.80M | (m) | (m) | (m) | $6.79M | (m) | 21.18× |
| 2026-03-31 | $263.23M | $9.12M | $206.39M | (m) | (m) | (m) | $5.44M | (m) | 28.88× |
| 2025-12-31 | $58.99M | $11.34M | $57.98M | (m) | (m) | (m) | $4.59M | (m) | 5.20× |
| 2025-09-30 | $66.94M | $10.31M | $63.57M | (m) | $0.00 | (m) | $3.48M | (m) | 6.49× |
| 2025-06-30 | $73.75M | $9.62M | $70.43M | (m) | $0.00 | (m) | $4.56M | (m) | 7.67× |
| 2025-03-31 | $79.44M | $8.98M | $75.63M | (m) | $0.00 | (m) | $4.44M | (m) | 8.84× |
| 2024-12-31 | $88.23M | $12.04M | $83.60M | (m) | $358.00K | (m) | $4.59M | (m) | 7.33× |
| 2023-12-31 | $7.55M | $2.36M | $7.35M | (m) | $0.00 | (m) | $936.00K | (m) | 3.20× |
| 2023-09-30 | $59.09M | $28.87M | $32.89M | (m) | $1.04M | (m) | $2.82M | (m) | 2.05× |
| 2023-06-30 | $66.47M | $34.37M | $44.94M | (m) | $952.00K | (m) | $7.60M | (m) | 1.93× |
| 2023-03-31 | $60.51M | $42.88M | $39.74M | (m) | $1.05M | (m) | $5.83M | (m) | 1.41× |
| 2022-12-31 | $73.42M | $36.58M | $38.63M | (m) | $5.81M | (m) | $4.15M | (m) | 2.01× |
| 2022-09-30 | $78.56M | $33.52M | $48.42M | (m) | $829.00K | (m) | $3.64M | (m) | 2.34× |
| 2022-06-30 | $90.90M | $35.55M | $54.26M | (m) | $1.26M | (m) | $1.90M | (m) | 2.56× |
| 2022-03-31 | $111.75M | $39.48M | $83.74M | (m) | $1.64M | (m) | $4.50M | (m) | 2.83× |
| 2021-12-31 | $127.63M | $50.56M | $117.76M | (m) | $3.31M | (m) | $8.61M | (m) | 2.52× |
| 2021-09-30 | $137.65M | $49.70M | $125.05M | (m) | $6.65M | (m) | $3.56M | (m) | 2.77× |
| 2021-06-30 | $127.67M | $43.93M | $119.10M | (m) | $2.80M | (m) | $2.31M | (m) | 2.91× |
| 2021-03-31 | $88.27M | $30.27M | $66.83M | (m) | $15.81M | (m) | $3.47M | (m) | 2.92× |
| 2020-12-31 | $75.72M | $22.14M | $70.44M | (m) | $1.71M | (m) | $1.79M | (m) | 3.42× |
| 2020-09-30 | $88.66M | $19.69M | $66.89M | (m) | $2.94M | (m) | $2.15M | (m) | 4.50× |
| 2020-06-30 | $92.03M | $18.26M | $44.30M | (m) | $10.71M | (m) | $4.41M | (m) | 5.04× |
| 2020-03-31 | $98.37M | $20.48M | $47.43M | (m) | $7.27M | (m) | $3.50M | (m) | 4.80× |
| 2019-12-31 | $115.01M | $27.00M | $62.26M | (m) | $6.79M | (m) | $5.80M | (m) | 4.26× |
| 2019-09-30 | $97.97M | $39.85M | $46.07M | (m) | $6.95M | (m) | $5.44M | (m) | 2.46× |
| 2019-06-30 | $111.46M | $40.93M | $54.90M | (m) | $7.17M | (m) | $4.03M | (m) | 2.72× |
| 2019-03-31 | $124.29M | $41.13M | $52.09M | (m) | $7.13M | (m) | $3.73M | (m) | 3.02× |
| 2018-12-31 | $135.38M | $48.08M | $74.87M | (m) | $2.70M | (m) | $3.35M | (m) | 2.82× |
| 2018-09-30 | $146.85M | $40.59M | $89.48M | (m) | $5.34M | (m) | $2.69M | (m) | 3.62× |
| 2018-06-30 | $156.60M | $52.33M | $50.58M | (m) | $2.56M | (m) | $3.17M | (m) | 2.99× |
| 2018-03-31 | $166.08M | $54.76M | $109.52M | (m) | $3.31M | (m) | $1.93M | (m) | 3.03× |
| 2017-12-31 | $89.79M | $45.77M | $37.88M | (m) | $15.55M | (m) | $2.45M | (m) | 1.96× |
| 2017-09-30 | $95.28M | $39.04M | $89.92M | (m) | $2.54M | (m) | $2.60M | (m) | 2.44× |
| 2017-06-30 | $102.74M | $35.80M | $50.33M | (m) | $48.47M | (m) | $4.65M | (m) | 2.87× |
| 2017-03-31 | $58.76M | $11.44M | $55.24M | (m) | $39.01K | (m) | $3.32M | (m) | 5.13× |
| 2016-12-31 | $32.67M | $8.38M | $29.36M | (m) | $57.00K | (m) | $2.39M | (m) | 3.90× |
| 2016-09-30 | $41.14M | $9.95M | $36.56M | (m) | (m) | (m) | (m) | (m) | 4.13× |
| 2016-06-30 | $43.88M | $6.42M | $40.37M | (m) | (m) | (m) | (m) | (m) | 6.84× |
| 2016-03-31 | $34.87M | $6.50M | $31.19M | (m) | $70.26K | (m) | (m) | (m) | 5.37× |
| 2015-12-31 | $31.66M | $2.80M | $29.35M | (m) | (m) | (m) | $1.06M | (m) | 11.32× |
| 2015-09-30 | $34.15M | $2.24M | $32.25M | (m) | $17.36K | (m) | (m) | (m) | 15.23× |
| 2015-06-30 | $12.64M | $3.02M | $10.03M | (m) | (m) | (m) | (m) | (m) | 4.18× |
| 2015-03-31 | $14.97M | $2.25M | $13.17M | (m) | (m) | (m) | (m) | (m) | 6.65× |
| 2014-12-31 | $19.81M | $3.52M | $18.47M | (m) | $0.00 | (m) | (m) | (m) | 5.63× |
| 2014-06-30 | $11.14K | $1.12K | $11.14K | (m) | (m) | (m) | $650.00 | (m) | 9.91× |
| 2013-12-31 | $4.82M | $1.77M | $3.69M | (m) | $481.81K | (m) | (m) | (m) | 2.73× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |